Roche CEO: Future of cancer treatment, AI in Medicine and Trial Challenges
2024/11/20
In Good Company with Nicolai Tangen
T
Thomas Schinecker
Thomas Schinecker认为基因组测序技术和抗体药物的进步是癌症治疗的重大突破，个性化癌症治疗是未来的重要方向。Roche在癌症治疗领域处于领先地位，持续加大研发投入，并通过内部研发和外部合作来推动创新。他还谈到了人工智能在药物研发中的应用，以及Roche如何通过人工智能提高研发效率和降低成本。此外，他还分析了欧洲和中国医药产业的现状和挑战，认为欧洲需要改善创业环境、减少官僚主义并加强人才培养。在药物定价方面，他认为需要考虑新药研发的漫长周期、高风险以及有限的市场独占期等因素，并主张采用差异化定价策略。
Nicolai Tangen主要就癌症治疗的进展、Roche在不同领域的市场地位、人工智能在医药领域的应用、欧洲与中国医药产业的竞争以及Roche的企业文化和领导力等方面与Thomas Schinecker进行了深入探讨，并就相关问题提出了自己的见解。
Deep Dive
Thomas Schinecker discusses the factors contributing to Basel's emergence as a leading biopharma hub, including its historical roots in the chemical industry, strategic location in the center of Europe, and the presence of a robust ecosystem with top universities and educational systems.
- Basel's history in the chemical industry laid the foundation for its biopharma growth.
- Strategic location in the center of Europe attracts global talent.
- Ecosystem includes top universities and educational systems fostering innovation.
Shownotes Transcript